ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,509.01
0.62%
US Tech 100
19,480.00
0.00%
Dow Jones
39,331.85
0.00%
Brent Oil
86.185
-0.30%
Bitcoin
60,113.90
-3.08%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Roivant Sciences Ltd (ROIV)

  7. Roivant Sciences Ltd (ROIV) News

ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ROIV
DateTimeSourceHeadlineSymbolCompany
08/03/20234:05PMGlobeNewswire Inc.Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023NASDAQ:ROIVRoivant Sciences Ltd
08/02/20234:05PMGlobeNewswire Inc.Roivant Announces Redemption of Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
07/27/20238:00AMGlobeNewswire Inc.Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s DiseaseNASDAQ:ROIVRoivant Sciences Ltd
07/14/20237:51AMIH Market NewsFriday’s Wall Street Highlights: JPMorgan Chase, Coinbase, UPS, Theseus Pharmaceuticals, and moreNASDAQ:ROIVRoivant Sciences Ltd
07/11/20238:00AMGlobeNewswire Inc.Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators ProgramNASDAQ:ROIVRoivant Sciences Ltd
06/28/20238:57AMGlobeNewswire Inc.UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
06/28/20237:00AMGlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
06/26/20234:05PMGlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023NASDAQ:ROIVRoivant Sciences Ltd
06/22/20237:30AMGlobeNewswire Inc.Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic PeriodNASDAQ:ROIVRoivant Sciences Ltd
06/21/20235:00PMGlobeNewswire Inc.Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative ColitisNASDAQ:ROIVRoivant Sciences Ltd
05/16/20237:00AMGlobeNewswire Inc.Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years OldNASDAQ:ROIVRoivant Sciences Ltd
04/04/20237:37AMBusiness WireLokavant Hires Experienced Leaders to Accelerate Growth TrajectoryNASDAQ:ROIVRoivant Sciences Ltd
04/04/20237:37AMBusiness WireLokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical ResearchNASDAQ:ROIVRoivant Sciences Ltd
03/28/20238:00AMGlobeNewswire Inc.Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer PatientsNASDAQ:ROIVRoivant Sciences Ltd
03/28/20238:00AMGlobeNewswire Inc.Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer PatientsNASDAQ:ROIVRoivant Sciences Ltd
03/15/20237:45AMGlobeNewswire Inc.Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years OldNASDAQ:ROIVRoivant Sciences Ltd
03/14/20234:07PMGlobeNewswire Inc.Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic DermatitisNASDAQ:ROIVRoivant Sciences Ltd
03/14/20238:00AMGlobeNewswire Inc.Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader ProgramsNASDAQ:ROIVRoivant Sciences Ltd
03/07/20238:00AMGlobeNewswire Inc.Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline AdvancementNASDAQ:ROIVRoivant Sciences Ltd
02/21/20238:32PMGlobeNewswire Inc.Roivant Sciences Announces Change to its Board of DirectorsNASDAQ:ROIVRoivant Sciences Ltd
02/13/20237:00AMGlobeNewswire Inc.Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
02/02/20239:14PMGlobeNewswire Inc.Roivant Sciences Announces Pricing of Upsized Public Offering of Common SharesNASDAQ:ROIVRoivant Sciences Ltd
02/01/20234:05PMGlobeNewswire Inc.Roivant Sciences Announces Proposed Public Offering of Common SharesNASDAQ:ROIVRoivant Sciences Ltd
01/30/20238:00AMGlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023NASDAQ:ROIVRoivant Sciences Ltd
01/04/20236:05AMGlobeNewswire Inc.Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker PositNASDAQ:ROIVRoivant Sciences Ltd
12/07/20226:30AMPR Newswire (US)Edison Partners leads $21 million funding round for clinical trial intelligence disruptor LokavantNASDAQ:ROIVRoivant Sciences Ltd
12/05/20228:35AMTipRanksJefferies Sticks to Their Buy Rating for Roivant Sciences (ROIV)NASDAQ:ROIVRoivant Sciences Ltd
12/01/20228:00AMGlobeNewswire Inc.Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic DiseasesNASDAQ:ROIVRoivant Sciences Ltd
11/15/20227:35AMTipRanksRoivant Sciences (ROIV) Gets a Buy from SVB SecuritiesNASDAQ:ROIVRoivant Sciences Ltd
11/15/20226:20AMTipRanksAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Roivant Sciences (ROIV) and Cullinan Management (CGEM)NASDAQ:ROIVRoivant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:ROIV

Your Recent History

NASDAQ
TSLA
Tesla
USOTC
NNAX
New Momentum (PK)
USOTC
CNNA
Cann American (CE)
USOTC
AABB
Asia Broadband (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
PHIL
PHI (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
AXXA
Exxe (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
BLLB
Bell Buckle (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
GGSM
Gold and GemStone Mining (PK)
USOTC
SMCE
SMC Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved